<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04087941</url>
  </required_header>
  <id_info>
    <org_study_id>HOPES</org_study_id>
    <nct_id>NCT04087941</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy -The HOPES Trial</brief_title>
  <official_title>Hepatocyte Growth Factor for Opioid-Dependent Pain: Efficacy and Safety of VM202 in Painful Diabetic Peripheral Neuropathy (The HOPES Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blind, randomized, placebo-controlled, single-center, 12-month phase 2 study&#xD;
      designed to assess the safety and efficacy of VM202 as a replacement for opioid analgesics in&#xD;
      opioid-tolerant subjects with painful diabetic peripheral neuropathy (DPN).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2019</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in 24-hour Morphine Milligram Equivalents (MME)</measure>
    <time_frame>baseline week to week prior to Day 180</time_frame>
    <description>The percent change in 24-hour MME use from baseline week to the week prior to Day 180 obtained from the Daily Pain and Sleep Interference Diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid use - mean dose</measure>
    <time_frame>Day 90, Day 180, Day 270, Day 365</time_frame>
    <description>mean dose of opioid reported in 24-hour MME at each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use - percent change from baseline</measure>
    <time_frame>Day 90, Day 180, Day 270, Day 365</time_frame>
    <description>percent change from baseline in 24-hour MME during the week prior to each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use - percent of subjects who are dose-reduced/opioid free</measure>
    <time_frame>Day 90, Day 180, Day 270, Day 365</time_frame>
    <description>percent of subjects whose daily opioid consumption is reduced by 50% and 100% (opioid-free) at each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid-Related AE - Cognition</measure>
    <time_frame>Day 90, Day 180, Day 270, Day 365</time_frame>
    <description>Cognition as measured with Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) assessed at each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid-Related AE - Bowel Function</measure>
    <time_frame>Day 90, Day 180, Day 270, Day 365</time_frame>
    <description>Bowel Function Inventory-revised (BFI-R) assessed at each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid-Related AE - Numerical Opioid Side Effect (NOSE)</measure>
    <time_frame>Day 90, Day 180, Day 270, Day 365</time_frame>
    <description>NOSE assessed at each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy- Change in Average Pain Intensity</measure>
    <time_frame>baseline week to week prior to Day 180</time_frame>
    <description>the change in average pain intensity from baseline week to the week prior to Day 180 obtained from the daily eDiaries</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Painful Diabetic Neuropathy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VM-202</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VM-202</intervention_name>
    <description>VM202 is a DNA plasmid that contains novel genomic cDNA hybrid human hepatocyte growth factor (HGF) coding sequence (HGF-X7) expressing two isoforms of HGF, HGF 728 and HGF 723.</description>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_label>VM-202</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years to 75 years;&#xD;
&#xD;
          2. Documented history of Type I or II diabetes with current treatment&#xD;
             control(glycosylated hemoglobin A1c of ≤ 10.0% at Screening) and currently on oral&#xD;
             medication and / or insulin;&#xD;
&#xD;
          3. Taking 60 to 200 mg morphine milligram equivalents (MME)/day for painful DPN at study&#xD;
             entry and must be on stable regimen starting at Day -21; percent of overall&#xD;
             requirement as immediate release must be ≥ 30%;&#xD;
&#xD;
          4. No significant changes anticipated in diabetes medication regimen;&#xD;
&#xD;
          5. No new symptoms associated with diabetes within the last 3 months prior to study&#xD;
             entry;&#xD;
&#xD;
          6. Diagnosis of painful diabetic peripheral neuropathy in both lower extremities;&#xD;
&#xD;
          7. Global pain intensity [Numerical rating scale, average NRS] score over the week prior&#xD;
             to initial Screening visit must be ≥ 4 and ≤ 9 (0 = no pain - 10 = worst pain&#xD;
             imaginable);&#xD;
&#xD;
          8. Symptoms from the Brief Pain Neuropathy Screening (BPNS) is ≤ 5 point difference&#xD;
             between legs at Initial Screening;&#xD;
&#xD;
          9. The physical examination component of the Michigan Neuropathy Screening Instrument&#xD;
             Score (MNSI) is ≥ 3 at Initial Screening;&#xD;
&#xD;
         10. Subjects on gabapentin (Neurontin), pregabalin (Lyrica), or duloxetine (Cymbalta) for&#xD;
             painful DPN at study entry must be on a stable regimen of these treatments for at&#xD;
             least 7 days prior to start of oral placebo run-in; and&#xD;
&#xD;
         11. If female of childbearing potential, negative urine pregnancy test at screening and&#xD;
             using acceptable method of birth control during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Small fiber polyneuropathy caused by condition other than diabetes;&#xD;
&#xD;
          2. Additional pain syndrome of overall greater intensity than that of DPN that, in the&#xD;
             opinion of the investigator, would prevent assessment of DPN;&#xD;
&#xD;
          3. Progressive or degenerative neurological disorder;&#xD;
&#xD;
          4. Myopathy;&#xD;
&#xD;
          5. Inflammatory disorder of the blood vessels (inflammatory angiopathy, such as Buerger's&#xD;
             disease);&#xD;
&#xD;
          6. Active infection, in the opinion of the investigator;&#xD;
&#xD;
          7. Chronic inflammatory disease (e.g., Crohn's disease, rheumatoid arthritis), in the&#xD;
             opinion of the investigator;&#xD;
&#xD;
          8. Positive HIV or HTLV at Screening;&#xD;
&#xD;
          9. Active Hepatitis B or C as determined by Hepatitis B core antibody (HBcAb; IgG and&#xD;
             IgM), antibody to Hepatitis B surface antigen (HBsAb), Hepatitis B surface antigen&#xD;
             (HBsAg) and Hepatitis C antibodies (Anti-HCV) at Screening;&#xD;
&#xD;
         10. Subjects with known immunosuppression or currently receiving immunosuppressive drugs,&#xD;
             chemotherapy or radiation therapy;&#xD;
&#xD;
         11. Stroke or myocardial infarction within last 3 months;&#xD;
&#xD;
         12. Specific laboratory values at Screening including: Hemoglobin &lt; 8.0 g/dL, WBC &lt; 3,000&#xD;
             cells per microliter, platelet count &lt;75,000/mm3, Creatinine &gt; 2.0 mg/dL; AST and/or&#xD;
             ALT &gt; 3 times the upper limit of normal or any other clinically significant lab&#xD;
             abnormality which in the opinion of the investigator should be exclusionary;&#xD;
&#xD;
         13. Proliferative retinopathy within 5 years of signing consent or any ophthalmological&#xD;
             condition which, in the opinion of the investigator, should be exclusionary; any&#xD;
             condition that precludes standard ophthalmologic examination;&#xD;
&#xD;
         14. Uncontrolled hypertension defined as sustained systolic blood pressure (SBP) &gt; 200&#xD;
             mmHg or diastolic BP (DBP) &gt; 110 mmHg at Screening;&#xD;
&#xD;
         15. Subjects with a recent history (&lt; 5 years) of or new screening finding of malignant&#xD;
             neoplasm except basal cell carcinoma or squamous cell carcinoma of the skin (if&#xD;
             excised and no evidence of recurrence for one year); subjects with family history of&#xD;
             colon cancer in any first degree relative are excluded unless they have undergone a&#xD;
             colonoscopy in the last 12 months with negative findings;&#xD;
&#xD;
         16. Use of the following drugs / therapeutics is PROHIBITED past Day -14:&#xD;
&#xD;
               -  skeletal muscle relaxants, benzodiazepines (except for stable bedtime dose),&#xD;
&#xD;
               -  capsaicin, local anesthetic creams and patches, isosorbide dinitrate (ISDN)&#xD;
                  spray,&#xD;
&#xD;
               -  transcutaneous electrical nerve stimulation (TENS), acupuncture&#xD;
&#xD;
         17. If not using gabapentin (Neurontin), pregabalin (Lyrica), duloxetine (Cymbalta), any&#xD;
             antidepressants (e.g., amitriptyline and venlafaxine), any other antiepileptics (e.g.,&#xD;
             valproic acid, carbamazepine, or vigabatrin), subjects must agree not to start these&#xD;
             drugs until after Day 180. Subjects on these medications on day of informed consent&#xD;
             must maintain a stable dose starting at Day -21 until Day 180; any changes in&#xD;
             analgesic regimen after Day 180 are at the discretion of the investigator;&#xD;
&#xD;
         18. Use of certain COX-1/COX-2 inhibitor drug(s), steroids (except inhaled, ocular, or&#xD;
             intra-articular steroids), and anti-Vascular Endothelial Growth Factor (VEGF) agents;&#xD;
             subjects may be enrolled if willing/able to undergo medication wash-out prior to the&#xD;
             first dosing and to refrain from taking these drugs for the duration of the study;&#xD;
&#xD;
         19. Major psychiatric disorder within last 6 months that would interfere with study&#xD;
             participation;&#xD;
&#xD;
         20. Body mass index (BMI) &gt; 45 kg/m2 at Screening;&#xD;
&#xD;
         21. Any prior or lower extremity amputation due to diabetic complications;&#xD;
&#xD;
         22. History of illicit drug or alcohol abuse / dependence in the past 2 years, including&#xD;
             but not limited to, cocaine, amphetamines, non-prescribed opioids, and non-prescribed&#xD;
             benzodiazepines);&#xD;
&#xD;
         23. Use of an investigational drug or treatment in past 6 months; and&#xD;
&#xD;
         24. Unable or unwilling to give informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christine N. Sang, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christine N. Sang, MD, MPH</last_name>
    <phone>617-525-7246</phone>
    <email>csang@bwh.harvard.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Translational Pain Research, Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 11, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2019</study_first_posted>
  <last_update_submitted>September 12, 2019</last_update_submitted>
  <last_update_submitted_qc>September 12, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Christine N. Sang, MD, MPH</investigator_full_name>
    <investigator_title>Director, Translational Pain Research</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
    <mesh_term>Pain</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

